NEW YORK, May 26, 2011 Reportlinker.com announces that a new market research report is available in its catalogue:
Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Advertisement
http://www.reportlinker.com/p0512133/Opioids-Market-to-2017---Steady-Uptake-of-Oxycontin-and-High-Incidence-Of-Diseases-Such-As-Cancer-And-Arthritis-to-Drive-the-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Advertisement
Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Summary
GBI Research, the leading business intelligence provider, has released its latest research, "Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market", which provides insights into global opioids market and market forecast until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which often opioids are prescribed which includes fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain. The report also examines the global opioids treatment usage patterns for the covered indication. In addition, the report also includes insights into the opioids R&D pipeline.
Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis shows that the overall global opioids market for the seven indications fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain was valued at $11.2 billion in 2010. The market is expected to witness a CAGR of 2.8% for the forecast period. Patent expiries of leading opioids followed by generic erosions along with adverse effects associated with use of opioids are the main reasons for marginal growth in opioids market. However expected launch of new opioids is expected to push the market in future.
The US was the largest region for the opioids market in terms of revenue, accounting for 49% followed by top five countries in Europe and Japan which contributed 36% and 15% respectively.
The top pharmaceutical companies in opioids market are - Johnson & Johnson, Cephalon and several mid size players such as Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.
Scope
The scope of this report includes -
- Data and analysis on the global opioids market.
- Annualized market data for the opioids market from 2002 to 2010, with forecasts to 2017.
- Market data on the therapeutic landscape which covers fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain therapeutics including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global opioids market which includes companies such as Johnson & Johnson, Cephalon, Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global opioids market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the region's opioids market.
- Develop key strategic initiatives by understanding the key focus areas and top selling opioids molecules of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Opioids Market to 2017: Introduction 11
2.1 GBI Research Report Guidance 11
3 Opioids Market: Market Overview 13
3.1 Introduction 13
3.2 Opioids: A Classification 13
3.2.1 Branded Generics Play a Major Role 15
3.2.2 Novel Drug Delivery Techniques Push Opioid Usage 15
3.3 Adverse Effects Associated With Opioids Restrain Its Prescription 16
3.4 REMS 17
3.4.1 What are REMS? 17
3.4.2 Implications of REMS 18
3.4.3 REMS for Opioids 19
3.5 Revenue 20
3.6 Major Marketed Opioids 21
3.6.1 Oxycontin 21
3.6.2 Embeda 22
3.6.3 Exalgo 23
3.6.4 Onsolis 24
3.6.5 Avinza 25
3.6.6 Duragesic 26
3.6.7 Kadian 27
3.6.8 Opana ER 27
3.6.9 Vicodin CR 28
3.6.10 Dolophine 29
3.6.11 MS Contin 30
3.6.12 Oramorph 30
3.7 FDA Regulations Regarding Opioids 33
3.7.1 FDA Regulations on Opioid Combinations with Acetaminophen 33
3.7.2 Darvocet, Darvon (Propoxyphene) Withdrawn From the Market 33
3.8 Annual Cost of Therapy 33
3.9 Treatment Usage Patterns 34
3.9.1 Diseased Population 36
3.9.2 Treatment Seeking Population 37
3.9.3 Diagnosed Population 38
3.9.4 Prescription Population 39
3.10 Drivers and Restraints of the Opioids Market 40
3.10.1 Drivers 40
3.10.2 Restraints 41
4 Opioids Market: Therapeutic Landscape 42
4.1 Opioids Market for Fibromyalgia 42
4.1.1 Introduction 42
4.1.2 Revenue and Forecasts 42
4.1.3 Annual Cost of Therapy 44
4.1.4 Treatment Usage Patterns 45
4.1.5 Geographical Segmentation 50
4.2 Drivers and Restraints for the Opioids Market for Fibromyalgia 52
4.2.1 Drivers 52
4.2.2 Restraints 53
4.3 Opioids for Neuropathic Pain 54
4.3.1 Introduction 54
4.3.2 Revenue and Forecasts 54
4.3.3 Annual Cost of Therapy 55
4.3.4 Treatment Usage Patterns 56
4.3.5 Geographical Segmentation 62
4.4 Drivers and Restraints for the Opioids Market for Neuropathic Pain 64
4.4.1 Drivers 64
4.4.2 Restraints 64
4.5 Opioids Market for Cancer Pain 65
4.5.1 Introduction 65
4.5.2 Revenue and Forecasts 66
4.5.3 Annual Cost of Therapy 67
4.5.4 Treatment Usage Patterns 68
4.5.5 Geographical Segmentation 74
4.5.6 Drivers and Restraints for the Opioids Market for Cancer Pain 76
4.5.7 Drivers 76
4.5.8 Restraints 77
4.6 Opioids Market for Osteoarthritis Pain 77
4.6.1 Introduction 77
4.6.2 Revenue and Forecasts 78
4.6.3 Annual Cost of Therapy 79
4.6.4 Treatment Usage Patterns 80
4.6.5 Geographical Segmentation 85
4.6.6 Drivers and Restraints for the Opioids Market for Osteoarthritis Pain 87
4.6.7 Drivers 87
4.6.8 Restraints 88
4.7 Opioids Market for Rheumatoid Arthritis Pain 88
4.7.1 Introduction 88
4.7.2 Revenue and Forecasts 88
4.7.3 Annual Cost of Therapy 89
4.7.4 Treatment Usage Patterns 91
4.7.5 Geographical Segmentation 96
4.7.6 Drivers and Restraints for Opioids Market for Rheumatoid Arthritis Pain 98
4.7.7 Drivers 98
4.7.8 Restrains 98
4.8 Opioids Market for Low Back Pain 99
4.8.1 Introduction 99
4.8.2 Revenue and Forecasts 99
4.8.3 Annual Cost of Therapy 100
4.8.4 Treatment Usage Patterns 101
4.8.5 Geographical Segmentation 106
4.8.6 Drivers and Restraints for the Opioids Market for Low Back Pain 108
4.8.7 Drivers 108
4.8.8 Restraints 108
4.9 Opioids Market for Post-operative Pain 109
4.9.1 Introduction 109
4.9.2 Revenue and Forecasts 109
4.9.3 Annual Cost of Therapy 110
4.9.4 Treatment Usage Patterns 111
4.9.5 Geographical Segmentation 117
4.9.6 Drivers and Restraints for the Opioids Market for Post-operative Pain 119
4.9.7 Drivers 119
4.9.8 Restraints 119
4.10 Opioids Market for Other Indications 120
4.10.1 Introduction 120
4.10.2 Revenue 120
5 Opioids Market: Geographical Landscape 121
5.1 The US 123
5.1.1 Revenue and Forecasts 123
5.1.2 Annual Cost of Therapy 125
5.1.3 Treatment Usage Patterns 126
5.2 Top Five Countries in Europe 132
5.2.1 Revenue and Forecasts 132
5.2.2 Annual Cost of Therapy 133
5.2.3 Treatment Usage Patterns 134
5.3 Japan 139
5.3.1 Revenue and Forecasts 139
5.3.2 Annual Cost of Therapy 140
5.3.3 Treatment Usage Patterns 141
6 Opioids Market: Pipeline Analysis 146
6.1 Introduction 146
6.1.1 Research and Development Pipeline - Neuropathic Pain 148
6.1.2 Research and Development Pipeline - Cancer Pain 149
6.2 Profiles of Key Late-Stage Drugs in the Opioids Market 149
6.2.1 Fentanyl TAIFUN - AKELA Pharma Inc. 149
6.2.2 Fentanyl Sublingual Spray - INSYS Therapeutics, Inc. 150
6.2.3 Oxycodone hydrochloride - Mundipharma International Limited 150
6.2.4 CEP-33237 - Cephalon, Inc. 150
6.2.5 ELI-216 - Elite Pharmaceuticals, Inc. 150
7 Opioids Market: Competitive Landscape 152
7.1 Competitive Profiling 152
7.1.1 King Pharmaceuticals 152
7.1.2 Johnson & Johnson 153
7.1.3 Orexo AB 155
7.1.4 Endo Pharmaceuticals 155
7.1.5 Cephalon, Inc. 157
7.1.6 Purdue Pharma 158
7.1.7 Mundipharma 159
8 Opioids Market: Strategic Consolidations 160
8.1 Overview 160
8.1.1 M&A Deals by Indication 160
8.1.2 M&A Deals by Geography 161
8.1.3 M&A Deals by Value ($) 162
8.2 R&D Licensing Agreements 165
8.2.1 Deals by Indication 165
8.2.2 Deals by Geography 166
8.2.3 Deals by Phase 167
8.2.4 Deals by Value ($) 168
8.2.5 Deals by Type 169
8.3 Co-development Deals 170
9 Opioids Market: Appendix 172
9.1 Market Definitions 172
9.2 Abbreviations 172
9.3 Research Methodology 173
9.3.1 Coverage 173
9.3.2 Secondary Research 174
9.3.3 Primary Research 174
9.3.4 Expert Panel Validation 176
9.4 Contact Us 176
9.5 Disclaimer 176
9.6 Sources 176
1.1 List of Tables
Table 1: Opioids Market, Global, Revenue ($bn), 2002-2010 21
Table 2: Opioids Market, Global Revenue ($bn), 2010-2017 21
Table 3: Global Revenue of Top Selling Opioids ($'000), 2007-2009 32
Table 4: Major Marketed Opioid Drugs 32
Table 5: Opioids Market, Global, Annual Cost of Therapy ($), 2002-2010 34
Table 6: Opioids Market, Global, Annual Cost of Therapy ($), 2010-2017 34
Table 7: Opioids Market, Global Treatment Usage Patterns (million), 2002-2010 35
Table 8: Opioids Market, Global Treatment Usage Patterns (million), 2010-2017 35
Table 9: Opioids Market, Fibromyalgia Global Revenue ($m), 2002-2010 43
Table 10: Opioids Market, Fibromyalgia Global Revenue ($m), 2010-2017 43
Table 11: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002-2010 44
Table 12: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2010-2017 44
Table 13: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2002-2010 45
Table 14: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2010-2017 46
Table 15: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002-2010 51
Table 16: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2010-2017 51
Table 17: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002-2010 55
Table 18: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2010-2017 55
Table 19: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002-2010 55
Table 20: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2010-2017 56
Table 21: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002-2010 57
Table 22: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2010-2017 58
Table 23: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002-2010 63
Table 24: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2010-2017 63
Table 25: Opioids Market, Global, Cancer Pain Revenue ($m), 2002-2010 67
Table 26: Opioids Market, Global, Cancer Pain Revenue ($m), 2010-2017 67
Table 27: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002-2010 67
Table 28: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2010-2017 68
Table 29: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002-2010 69
Table 30: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2010-2017 69
Table 31: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002-2010 75
Table 32: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2010-2017 75
Table 33: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002-2010 78
Table 34: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2010-2017 78
Table 35: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002-2010 79
Table 36: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2010-2017 79
Table 37: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002-2010 80
Table 38: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2010-2017 81
Table 39: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2002-2010 86
Table 40: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2010-2017 86
Table 41: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002-2010 89
Table 42: Opioids Market, Rheumatoid Arthritis Global Revenue ($m), 2010-2017 89
Table 43: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002-2010 90
Table 44: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2010-2017 90
Table 45: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns ('000), 2002-2010 91
Table 46: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns ('000), 2010-2017 92
Table 47: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002-2010 97
Table 48: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2010-2017 97
Table 49: Opioids Market, Low Back Pain Global Revenue ($m), 2002-2010 99
Table 50: Opioids Market, Low Back Pain Global Revenue ($m), 2010-2017 99
Table 51: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002-2010 100
Table 52: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2010-2017 100
Table 53: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002-2017 101
Table 54: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2010-2017 102
Table 55: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002-2010 107
Table 56: Opioids Market, Global, Low Back Pain Market Geographical Segmentation ($m), 2010-2017 107
Table 57: Opioids Market, Post Operative Pain Global Revenue ($bn), 2002-2010 110
Table 58: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2010-2017 110
Table 59: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002-2010 110
Table 60: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2010-2017 111
Table 61: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002-2010 112
Table 62: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2010-2017 112
Table 63: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002-2010 118
Table 64: Opioids Market, Global, Post Operative Pain Market Geographical Segmentation ($m), 2010-2017 118
Table 65: Opioids Market, Others Global Revenue ($m), 2002-2010 120
Table 66: Opioids Market, Others Global Revenue ($m), 2010-2017 120
Table 67: Opioids Market, Global, Revenues by Geography ($bn), 2002-2010 122
Table 68: Opioids Market, Global, Revenues by Geography ($bn), 2010-2017 122
Table 69: Opioids Market, The US, Revenues ($bn), 2002-2010 124
Table 70: Opioids Market, The US, Revenues ($bn), 2010-2017 124
Table 71: Opioids Market, The US, Annual Cost of Therapy ($), 2002-2010 125
Table 72: Opioids Market, The US, Annual Cost of Therapy ($), 2010-2017 125
Table 73: Opioids Market, The US, Treatment Usage Pattern (million), 2002-2010 126
Table 74: Opioids Market, The US, Treatment Usage Pattern (million), 2010-2017 127
Table 75: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2002-2010 132
Table 76: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2010-2017 132
Table 77: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 133
Table 78: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 133
Table 79: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010 134
Table 80: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017 135
Table 81: Opioids Market, Japan, Revenues ($bn), 2002-2010 139
Table 82: Opioids Market, Japan, Revenues ($bn), 2010-2017 139
Table 83: Opioids Market, Japan Annual Cost of Therapy, ($), 2002-2010 140
Table 84: Opioids Market, Japan Annual Cost of Therapy, ($), 2010-2017 140
Table 85: Opioids Market, Japan, Treatment Usage Pattern (million), 2002-2010 141
Table 86: Opioids Market, Japan, Treatment Usage Pattern (million), 2010-2017 142
Table 87: Opioids Market, Global Major M&A Deals, 2009-2011 163
Table 88: Opioids Market, Global Major Co-developments Deals , 2009-2010 171
1.2 List of Figures
Figure 1: Opioids - A Classification 14
Figure 2: Opioids - Adverse Effects 16
Figure 3: Risk Evaluation and Mitigation Strategy, Components of REMS 17
Figure 4: Risk Evaluation and Mitigation Strategy, Implications for Patients 18
Figure 5: Risk Evaluation and Mitigation Strategy, Number of ED Visits Due To Drug Abuse in the US, 2004 and 2008 20
Figure 6: Opioids Market, Global, Revenue ($bn), 2002-2017 20
Figure 7: Global Revenue of Top Selling Opioids,($'000), 2007-2009 31
Figure 8: Opioids Market, Global, Annual Cost of Therapy ($), 2002-2017 33
Figure 9: Opioids Market, Global Therapeutic Usage Patterns, 2002-2017 34
Figure 10: Opioids Market, Global Diseased Population (million), 2002-2017 36
Figure 11: Opioids Market, Global Treatment Seeking Population (million), 2002-2017 37
Figure 12: Opioids Market, Global Diagnosed Population (million), 2002-2017 38
Figure 13: Opioids Market, Global Prescription Population (million), 2002-2017 39
Figure 14: Opioids Market, Drivers and Restraints, 2010 40
Figure 15: Opioids Market, Fibromyalgia, Global Revenue ($m), 2002-2017 42
Figure 16: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002-2017 44
Figure 17: Opioids Market, Fibromyalgia Global Treatment Usage Pattern (million), 2002-2017 45
Figure 18: Opioids Market, Fibromyalgia Global Diseased Population (million), 2002-2017 46
Figure 19: Opioids Market, Fibromyalgia Global Treatment Seeking Population (million), 2002-2017 47
Figure 20: Opioids Market, Fibromyalgia Global Diagnosis Population (million), 2002-2017 48
Figure 21: Opioids Market, Fibromyalgia Global Prescription Population (million), 2002-2017 49
Figure 22: Opioids Market, Fibromyalgia Global Market Segmentation by Geography (%), 2010 and 2017 50
Figure 23: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002-2017 51
Figure 24: Opioids Market, Fibromyalgia Drivers and Restraints, 2010 53
Figure 25: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002-2017 54
Figure 26: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002-2017 55
Figure 27: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002-2017 57
Figure 28: Opioids Market, Global, Neuropathic Pain Diseased Population (million), 2002-2017 58
Figure 29: Opioids Market, Global, Neuropathic Pain Treatment Seeking Population (million), 2002-2017 59
Figure 30: Opioids Market, Global, Neuropathic Pain Diagnosis Population (million), 2002-2017 60
Figure 31: Opioids Market, Global, Neuropathic Pain Prescription Population (million), 2002-2017 61
Figure 32: Opioids Market, Global, Neuropathic Pain Market Segmentation by Geography, 2010 and 2017 62
Figure 33: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002-2017 63
Figure 34: Opioids Market, Neuropathic Pain Global Drivers and Restraints, 2010 65
Figure 35: Opioids Market, Global, Cancer Pain Revenue ($bn), 2002-2017 66
Figure 36: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002-2017 67
Figure 37: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002-2017 68
Figure 38: Opioids Market, Global, Cancer Pain Diseased Population (million), 2002-2017 70
Figure 39: Opioids Market, Global, Cancer Pain Treatment Seeking Population (million), 2002-2017 71
Figure 40: Opioids Market, Global, Cancer Pain Diagnosis Population (million), 2002-2017 72
Figure 41: Opioids Market, Global, Cancer Pain Opioid Prescription Population (million), 2002-2017 73
Figure 42: Opioids Market, Global, Cancer Pain Market Segmentation by Geography, 2010 and 2017 74
Figure 43: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002-2017 75
Figure 44: Opioids Market, Cancer Pain Drivers and Restraints, 2010 76
Figure 45: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002-2017 78
Figure 46: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002-2017 79
Figure 47: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002-2017 80
Figure 48: Opioids Market, Osteoarthritis Pain Global Diseased Population (million), 2002-2017 81
Figure 49: Opioids Market, Osteoarthritis Pain Global Treatment Seeking Population (million), 2002-2017 82
Figure 50: Opioids Market, Osteoarthritis Pain Global Diagnosis Population (million), 2002-2017 83
Figure 51: Opioids Market, Osteoarthritis Pain Global Prescription Population (million), 2002-2017 84
Figure 52: Opioids Market, Osteoarthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 85
Figure 53: Opioids Market, Osteoarthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 86
Figure 54: Opioids Market, Osteoarthritis Pain Drivers and Restraints, 2010 87
Figure 55: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002-2017 88
Figure 56: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002-2017 89
Figure 57: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns (million), 2002-2017 91
Figure 58: Opioids Market, Rheumatoid Arthritis Pain Global Diseased Population (million), 2002-2017 92
Figure 59: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Seeking Population (million), 2002-2017 93
Figure 60: Opioids Market, Rheumatoid Arthritis Pain Global Diagnosis Population (million), 2002-2017 94
Figure 61: Opioids Market, Rheumatoid Arthritis Pain Global Prescription Population (million), 2002-2017 95
Figure 62: Opioids Market, Rheumatoid Arthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017 96
Figure 63: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002-2017 97
Figure 64: Opioids Market, Rheumatoid Arthritis Pain Drivers and Restraints, 2010 98
Figure 65: Opioids Market, Low Back Pain Global Revenue ($m), 2002-2017 99
Figure 66: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002-2017 100
Figure 67: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002-2017 101
Figure 68: Opioids Market, Low Back Pain Global Diseased Population (million), 2002-2017 102
Figure 69: Opioids Market, Low Back Pain Global Treatment Seeking Population (million), 2002-2017 103
Figure 70: Opioids Market, Low Back Pain Global Diagnosis Population (million), 2002-2017 104
Figure 71: Opioids Market, Low Back Pain Global Prescription Population (million), 2002-2017 105
Figure 72: Opioids Market, Low Back Pain Global Market Segmentation by Geography (%), 2010 and 2017 106
Figure 73: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002-2017 107
Figure 74: Opioids Market, Low Back Pain Drivers and Restraints, 2010 108
Figure 75: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2002-2017 109
Figure 76: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002-2017 110
Figure 77: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002-2017 111
Figure 78: Opioids Market, Post Operative Pain Global Diseased Population (million), 2002-2017 113
Figure 79: Opioids Market, Post Operative Pain Global Treatment Seeking Population (million), 2002-2017 114
Figure 80: Opioids Market, Post Operative Pain Global Diagnosis Population (million), 2002-2017 115
Figure 81: Opioids Market, Post Operative Pain Global Prescription Population (million), 2002-2017 116
Figure 82: Opioids Market, Post Operative Pain Global Market Segmentation by Geography (%), 2010 and 2017 117
Figure 83: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002-2017 118
Figure 84: Opioids Market, Post Operative Pain Drivers and Restraints, 2010 119
Figure 85: Opioids Market, Others Global Revenue ($m), 2002-2017 120
Figure 86: Opioids Market, Global, Market Share by Geography (%), 2010 and 2017 121
Figure 87: Opioids Market, Global, Revenues by Geography ($bn), 2002-2017 122
Figure 88: Opioids Market, Top Five Countries in Europe, Revenues ($), 2002-2017 123
Figure 89: Opioids Market, The US, Annual Cost of Therapy ($), 2002-2017 125
Figure 90: Opioids Market, The US, Treatment Usage Pattern (million), 2002-2017 126
Figure 91: Opioids Market, The US, Diseased Population (million), 2002-2017 128
Figure 92: Opioids Market, The US, Treatment Seeking Population (million), 2002-2017 129
Figure 93: Opioids Market, The US, Diagnosed Population (million), 2002-2017 130
Figure 94: Opioids Market, The US, Prescription Population (million), 2002-2017 131
Figure 95: Opioids Market, Top Five Countries in Europe, Revenues ($), 2002-2017 132
Figure 96: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 133
Figure 97: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017 134
Figure 98: Opioids Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017 135
Figure 99: Opioids Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017 136
Figure 100: Opioids Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017 137
Figure 101: Opioids Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017 138
Figure 102: Opioids Market, Japan, Revenues ($), 2002-2017 139
Figure 103: Opioids Market, Japan, Annual Cost of Therapy ($), 2002-2017 140
Figure 104: Opioids Market, Japan, Treatment Usage Pattern (million), 2002-2017 141
Figure 105: Opioids Market, Japan, Diseased Population (million), 2002-2017 142
Figure 106: Opioids Market, Japan, Treatment Seeking Population (million), 2002-2017 143
Figure 107: Opioids Market, Japan, Diagnosis Population (million), 2002-2017 144
Figure 108: Opioids Market, Japan, Prescription Population (million), 2002-2017 145
Figure 109: Opioids Market, Global, R&D Pipeline by Indication (%), March 2010 146
Figure 110: Opioids Market, Global, R&D Pipeline by Phase (%), March 2010 147
Figure 111: Opioids Market, Global, Neuropathic Pain R&D Pipeline by Phase (%), 2010 148
Figure 112: Opioids Market, Global, Cancer Pain R&D Pipeline by Phase (%), 2010 149
Figure 113: Opioids Market, Global, SWOT - King Pharmaceuticals, 2010 152
Figure 114: Opioids Market, Global, SWOT - Johnson & Johnson, 2010 154
Figure 115: Opioids Market, Global, SWOT - Orexo, 2010 155
Figure 116: Opioids Market, Global, SWOT - Endo Pharmaceuticals, 2010 156
Figure 117: Opioids Market, Global, SWOT - Cephalon, 2010 157
Figure 118: Opioids Market, Global, SWOT - Purdue Pharma, 2010 158
Figure 119: Opioids Market, Global, SWOT - Mundipharma, 2010 159
Figure 120: Opioids Market, Global, M&A Deals by Indication (%), 2005-2010 160
Figure 121: Opioids Market, Global, M&A Deals by Geography (%), 2005-2010 161
Figure 122: Opioids Market, Global, M&A Deals by Value (%), 2005-2010 162
Figure 123: Opioids Market, Global, Major Licensing Agreements by Indication (%), 2009-2010 165
Figure 124: Opioids Market, Global, Major Licensing Agreements by Geography (%), 2009-2010 166
Figure 125: Opioids Market, Global, Major Licensing Agreements by Phase (%), 2009-2010 167
Figure 126: Opioids Market, Global, Major Licensing Agreements by Value (%), 2009-2010 168
Figure 127: Opioids Market, Global, Major Licensing Agreements by Type (%), 2009-2010 169
Figure 128: Opioids Market, Global, Co-Development Deals By Indication (%), 2009-2010 170
Figure 129: Opioids Market, Global, Co-Development Deals By Geography (%), 2009-2010 170
Figure 130: GBI Research Market Forecasting Model 175
Companies Mentioned
King Pharmaceuticals
Johnson & Johnson
Orexo AB
Endo Pharmaceuticals
Cephalon, Inc.
Purdue Pharma
Mundipharma
To order this report:
Drug and Medication Industry: Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
